Despite the strong pre-clinical rationale for combining HER2-targeted therapies with anti-angiogenic drugs, there was no overall benefit, and there was added toxicity of combining bevacizumab with trastuzumab and chemotherapy, aligning with the 2011 FDA decision to remove the recommendation for the use of bevacizumab in all breast cancers. Here, ERBB2 is linked to breast carcinoma.